While novel echocardiographic techniques hold promise for assessing right ventricular function in pulmonary arterial hypertension, only TAPSE and pericardial effusion currently have sufficient evidence to guide therapy adjustment.
Answers are grounded in this paper and cite their sources.
Supports limiting PAH therapy adjustment to TAPSE and effusion; leaves open validation of novel RV imaging techniques.
In theory, echocardiography allows an accurate measurement of pulmonary artery pressure, approximate right atrial pressure, cardiac output, right ventricular diastolic function and non-volumetric assessment of systolic function, as well as some insight into the structural alterations of right ventricular architecture. Unfortunately, the vast array of possible measures complicates distillation of the few parameters that provide reproducible prognostically important information. The modest reductions in afterload achieved with current therapies (<5mmHg on average) and the unpredictability of right ventricular response, coupled with the complexity of the populations treated, means that only large-scale survival studies should be considered when determining which parameters inform patient management. Of currently widely used measures, only tricuspid annular plane systolic excursion (TAPSE) and pericardial effusion are recommended when adjusting therapy. Increased use of contrast echo, strain rate imaging, vector velocity imaging and 3D echocardiography appear to hold most hope for the future; however, none as yet has the database to support inclusion in standard clinical practice.
No takes yet. Share an insight, caveat, or question.
Coghlan et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: